Active Ingredient History
Lutetium Lu 177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSRT2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta emission from Lu 177 induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells. LUTATHERA® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (Phase 2)
Carcinoid Tumor (Phase 2)
Carcinoma, Neuroendocrine (Phase 2)
Clinical Trial, Phase I (Phase 1)
Drugs, Investigational (Phase 2)
Glioblastoma (Phase 1)
Glioma (Phase 2)
Intestinal Neoplasms (Phase 3)
Lung Neoplasms (Phase 2)
Meningioma (Phase 2)
Mesothelioma (Phase 1)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 1)
Neuroblastoma (Phase 2)
Neuroendocrine Tumors (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 3)
Paraganglioma (Phase 2)
Pheochromocytoma (Phase 2)
Pituitary Neoplasms (Phase 2)
Small Cell Lung Carcinoma (Phase 1)
Thymoma (Phase 1)
Thyroid Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue